FDA grants accelerated approval to futibatinib for cholangiocarcinoma

On September 30, 2022, the Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients.

Source: FDA Center for Drug Evaluation and Research - What's New - September 30, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news